Cargando…

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens

BACKGROUND: There are conflicting data regarding the risk of hepatocellular carcinoma (HCC) after direct-acting antiviral agent (DAA) treatment. Risk of HCC in HCV genotype-3 infected persons after DAA therapy is not well known. METHODS: We prospectively studied HCV infected persons initiated on a D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tayyab, Ghias Un Nabi, Rasool, Shafqat, Nasir, Bilal, Rubi, Ghazala, Abou-Samra, Abdul-Badi, Butt, Adeel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137260/ https://www.ncbi.nlm.nih.gov/pubmed/32252635 http://dx.doi.org/10.1186/s12876-020-01249-4

Ejemplares similares

304. Hepatocellular Carcinoma Occurs Frequently and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens
por: Un Nabi Tayyab, Ghias, et al.
Publicado: (2019)

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Risk of Covid-19 infection during endoscopy: Efficacy of personal protective equipment (PPE) in protecting health professionals
por: Dilshad, Muhammad Akif, et al.
Publicado: (2021)

HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
por: Butt, Adeel A., et al.
Publicado: (2015)

930. HCV Treatment Is Associated With a Reduced Risk of Cardiovascular Disease Events: Results From ERCHIVES
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study
por: Li, Darrick K, et al.
Publicado: (2017)

Post-transplantation lymphoproliferative disorder with gastrointestinal involvement
por: Inayat, Faisal, et al.
Publicado: (2018)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
por: Dawood, Reham M., et al.
Publicado: (2022)

Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Márquez-Coello, Mercedes, et al.
Publicado: (2021)

Impact of COVID-19 upon changes in emergency room visits with chest pain of possible cardiac origin
por: Butt, Adeel A., et al.
Publicado: (2020)

Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use
por: Butt, Adeel A., et al.
Publicado: (2021)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ggb1qgitikul0c9ld8vkk2du5g